2022
First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
Fong K, Zhao J, Sultana R, Lee J, Lee S, Chan S, Yau T, Tai D, Sundar R, Too C. First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis. Liver Cancer 2022, 12: 7-18. PMID: 36872922, PMCID: PMC9982345, DOI: 10.1159/000526639.Peer-Reviewed Original ResearchAdvanced hepatocellular carcinomaProgression-free survivalFirst-line systemic therapyBarcelona Clinic Liver CancerNetwork meta-analysisOverall survivalStandard of careAlpha-fetoproteinHazard ratioOS benefitSystemic therapyFirst-lineHepatocellular carcinomaFirst-line combination therapyRandom-effects network meta-analysisCombination of atezolizumabInhibitor monoclonal antibodiesFirst-line therapyCochrane Controlled Register of TrialsMeta-analysisKaplan-Meier curvesIndividual patient-level dataCochrane Controlled RegisterRegister of TrialsExtrahepatic spread
2020
Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.
Low J, Sooi K, Huang Y, Chan G, Ang Y, Chong W, Tan H, Ngoi N, Choo J, Lee M, Muthu V, Asokumaran Y, Walsh R, Wong R, Chan Z, Soo R, Sundar R, Yong W. Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia. Journal Of Clinical Oncology 2020, 38: e19385-e19385. DOI: 10.1200/jco.2020.38.15_suppl.e19385.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerProgression free survivalFree survivalFixed doseTreatment of non-small cell lung cancer patientsOncogenic driversNon-small cell lung cancer patientsTreatment of non-small cell lung cancerCell lung cancer patientsResponse rateTreated with pembrolizumabDose of pembrolizumabEfficacy of pembrolizumabKaplan Meier methodUS Food and Drug AdministrationSurvival of patientsCell lung cancerLow dose groupLung cancer patientsNational University HospitalFood and Drug AdministrationStandard of careECOG 0Overall survival
2019
A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).
Lim J, Wong A, Ow S, Eng L, Sundar R, Chan G, Yadav K, Heong V, Tan D, Soo R, Chee C, Yong W, Goh B, Lee S. A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC). Journal Of Clinical Oncology 2019, 37: 1045-1045. DOI: 10.1200/jco.2019.37.15_suppl.1045.Peer-Reviewed Original ResearchDose-limiting toxicityDisease control ratePalmar-plantar erythrodysesthesiaDose reductionBreast cancerDose levelsMechanisms of endocrine resistanceRecommended phase 2 dosePhase 2 doseAdvanced/metastatic breast cancerHR+ breast cancerPhase Ib trialContinuous daily dosingSerial tumor biopsiesAnti-tumor activityStandard of careDose expansionG3 toxicityPrior CTPostmenopausal womenTumor biopsiesEndocrine resistanceDaily doseEstrogen receptorPreclinical studies